Gilead Sciences Inc. said its two hepatitis C drugs, Sovaldi and Harvoni, generated $4.8 billion in sales in the third quarter, topping Wall Street estimates for global sales of $4.47 billion.
from WSJ.com: US Business http://ift.tt/1Mr1rCK
via IFTTT
No comments:
Post a Comment